Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 34, Issue 3-4, 2009, Pages 221-227

  Li, Yunxia ^a   Jiang, Xuehua ^a   Lan, Ke ^a   Jiang, Qian ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chinese; Pharmacokinetics; Rosuvastatin; Single and multiple doses

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CREATINE KINASE; ROSUVASTATIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHINESE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 72149109265     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191177     Document Type: Article

References (10)

1. th Edition, 948-953.
2. Nezasa K., Hasega H., (2000): Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat. Atherosclerosis, 151, 39-42.
3. Nezasa K., Higaki K., Matsumura T., Inazawa K, Hasegawa H., Nakano M., Koike M., (2002): Liver specific distribution of rosuvastatin in rats: Comparison with pravastatin and simvastatin. Drug Metab. Disp., 30, 1158-1163.
4. Brown CDA, W.A., Bleasby K., Lauffart B., (2001): Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C, Atherosclerosis, Suppl 2, 90-96.
5. McCormick A.D., Butters C.J., (2000): ZD4522-an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems. J. Clin. Pharmacol., 40, 1055-1062.
6. Martin P.D.M., D.W. Schneck, Br. J., (2002): No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor, Clin. Pharmacol., 54, 472-477.
7. Lee E., Ryan S., Birminghan B., Zalikowski J., March R., Ambrose H., Moore R., Lee C., Chen Y., Schneck D., (2005): Rosuvastatin pharmacokinrtics and pharmacogenetics in white and Asian subjects residing in the same environment, Clin. pharmacol. Ther., 78, 311-316.
8. Warwick M.J., Dane A.L., Raza A., Schneck D.W., (2000): Single. and multiple-dose pharmacokinetics and safety of the new HMG-CoA rednctase inhibitor ZD4522, Atherosclerosis, 150, 12-17.
9. Schneck D.W., Birmingham B.K., Zalikowski J.A., Mitchell P.D., Wang Y., Martin P.D., Lasseter K.C., Brown C.D., Windass A.S., Raza A., (2004): The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther., 75, 455-463.
10. Schneck D.W., Birmingham B.K., Zalikowski J.A., Mitchell P.D., Wang Y., Martin P.D., Lasseter K.C., Brown C.D., Windass A.S., Raza A., (2004): The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther., 75, 455-463.